Evaluation of Drug Adverse Event Intake and Reporting in a Medical Information Service

被引：0
|
作者：
Pamela D. Allen
Robert J. Fuentes
Michael J. Hoopes
Greg Susla
机构：
[1] MedImmune,Medical Information Resident
[2] LLC,Medical Information and Scientific Communications
[3] MedImmune,Medical Information
[4] LLC,Medical Communications Consultant, Xcenda
[5] MedImmune,undefined
[6] LLC,undefined
[7] AmerisourceBergen Consulting Services,undefined
来源：
Drug information journal : DIJ / Drug Information Association | 2011年 / 45卷
关键词：
Data; Adverse events; Pharmaceutical industry; Drug information; Medical information service;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：767 / 773
页数：6
相关论文
共 50 条
  • [41] ADVERSE DRUG EVENT REPORTING - IMPROVING THE LOW UNITED-STATES REPORTING RATES
    EDLAVITCH, SA
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1988, 148 (07) : 1499 - 1503
  • [42] Adverse Drug Event Reporting Rates After the Implementation of an EHR Integrated Reporting System
    Correa, Eunice
    Ignacio Jauregui, Oscar
    Frangella, Julia
    Peuchot, Veronica
    Otero, Carlos
    Luna, Daniel
    [J]. MEDINFO 2019: HEALTH AND WELLBEING E-NETWORKS FOR ALL, 2019, 264 : 1652 - 1653
  • [43] Implementation of mandatory adverse event reporting for botanicals: Are we collecting and reporting meaningful information?
    Kingston, R. L.
    [J]. PLANTA MEDICA, 2008, 74 (03) : 319 - 319
  • [44] Adverse drug reactions in neonates: a brief analysis of the FDA adverse event reporting system
    Byskov, Pernille Kahler
    Baden, Christoffer Storm
    Andersen, Jon Traerup
    Jimenez-Solem, Espen
    Olsen, Ramus Huan
    Gade, Christina
    Lausten-Thomsen, Ulrik
    [J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [45] Introduction of a Mobile Adverse Event Reporting System Is Associated With Participation in Adverse Event Reporting
    Rubin, Daniel S.
    Pesyna, Colin
    Jakubczyk, Sharon
    Liao, Chuanhong
    Tung, Avery
    [J]. AMERICAN JOURNAL OF MEDICAL QUALITY, 2019, 34 (01) : 30 - 35
  • [46] Comparisons of adverse event reporting for colistin versus polymyxin B using the US Food and Drug Administration Adverse Event Reporting System (FAERS)
    Cong Bang Truong
    Durham, Spencer H.
    Qian, Jingjing
    [J]. EXPERT OPINION ON DRUG SAFETY, 2021, 20 (05) : 603 - 609
  • [47] Drug Interaction Between Febuxostat and Thiopurine Antimetabolites: A Review of the FDA Adverse Event Reporting System and Medical Literature
    Logan, Jill K.
    Yapa, Shalini Wickramaratne Senarath
    Harinstein, Lisa
    Saluja, Bhawana
    Munoz, Monica
    Sahajwalla, Chandrahas
    Neuner, Rosemarie
    Seymour, Sally
    [J]. PHARMACOTHERAPY, 2020, 40 (02): : 125 - 132
  • [48] Evaluation of a prospective adverse event reporting system in interventional radiology
    Mulvihill, S. B.
    Healy, G. M.
    O'Rourke, C.
    Cantwell, C. P.
    [J]. CLINICAL RADIOLOGY, 2021, 76 (09) : 659 - 664
  • [49] Adverse event profiles of ifosfamide-induced encephalopathy analyzed using the Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases
    Shimada, Kazuyo
    Hasegawa, Shiori
    Nakao, Satoshi
    Mukai, Ririka
    Matsumoto, Kiyoka
    Tanaka, Mizuki
    Uranishi, Hiroaki
    Masuta, Mayuko
    Nishida, Shohei
    Shimizu, Shinya
    Hayashi, Yuichi
    Nakamura, Mitsuhiro
    Suzuki, Akio
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (05) : 1097 - 1105
  • [50] Adverse event profiles of ifosfamide-induced encephalopathy analyzed using the Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases
    Kazuyo Shimada
    Shiori Hasegawa
    Satoshi Nakao
    Ririka Mukai
    Kiyoka Matsumoto
    Mizuki Tanaka
    Hiroaki Uranishi
    Mayuko Masuta
    Shohei Nishida
    Shinya Shimizu
    Yuichi Hayashi
    Akio Suzuki
    Mitsuhiro Nakamura
    [J]. Cancer Chemotherapy and Pharmacology, 2019, 84 : 1097 - 1105
12345